Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alterra Biotech appears to have been an early-stage biotechnology company or university spinout associated with Princeton University. Publicly available evidence is sparse, but third-party references identify Robert Hart as founder and CEO and describe the business as operating in biotechnology. The company was listed in life-science partnering materials, suggesting it was active in the Northeast biotech ecosystem around 2020. No validated evidence of an active therapeutic pipeline, clinical-stage assets, approved products, or continuing operations was found. Based on the limited record, Alterra Biotech is best characterized as a historical private biotech entity with insufficient public disclosure to support detailed pipeline analysis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alterra Biotech.